CD47 polymorphism for predicting nivolumab benefit in patients with advanced non‑small‑cell lung cancer

Immune checkpoint inhibitors (ICIs), such as nivolumab, play an essential role in non-small-cell lung cancer (NSCLC) treatment. Programmed death ligand-1 has been used as a predictive biomarker for the efficacy of ICI treatment in patients with NSCLC; however, its predictive value is considered insu...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogimoto, Tatsuya, Ozasa, Hiroaki, Yoshida, Hironori, Nomizo, Takashi, Funazo, Tomoko, Yoshida, Hiroshi, Hashimoto, Kentaro, Hosoya, Kazutaka, Yamazoe, Masatoshi, Ajimizu, Hitomi, Tsuji, Takahiro, Sakamori, Yuichi, Kuninaga, Kiyomitsu, Morita, Satoshi, Hirai, Toyohiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398628/
https://www.ncbi.nlm.nih.gov/pubmed/37545625
http://dx.doi.org/10.3892/ol.2023.13950

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398628/
https://www.ncbi.nlm.nih.gov/pubmed/37545625
http://dx.doi.org/10.3892/ol.2023.13950

Ejemplares similares